Investor BriefingMay 2009F

or p

erso

nal u

se o

nly

2

DISCLAIMER

The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions.This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law.Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor. Certain statements made in this presentation are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Clover Corporation’s current expectations, estimates and projections about the industry in which Clover Corporation operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks,” "estimates," and similar expressions are intended to identify forward-looking statements.These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Clover Corporation, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Clover Corporation cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Clover Corporationonly as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Clover Corporation will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

For

per

sona

l use

onl

y

3

Clover Corporation provides nutritional and functional ingredients for use in foods and specialty applications using proprietary

technology. The current primary activities of the company are involved with the provision of HiDHA® omega-3 fish oils/powders

and debittered soy ingredients.

Future FoodFuture FoodIngredientsIngredients

(50%)(100%)

INTRODUCTION

For

per

sona

l use

onl

y

4

COMPANY OVERVIEW

• Mission is to identify, develop and commercialise specialty functional and nutritional ingredients with an initial focus on HiDHA® marine oils.

• Clover Corporation was founded in 1988 and listed on the ASX in 1999.

• Nu-Mega Ingredients was founded as a JV in 2003 and fully acquired in November 2007.

• Consistently profitable, strong cash position & zero debt.• Competitive position in the growing “nutraceutical” market.• Strong technical, manufacturing and sales organisation.• Focus on proprietary technology, such as microencapsulation.

For

per

sona

l use

onl

y

5

Shares on issue 165.18 million 165.18 million

Total contributed equity $32.92 million $32.92 million

Market capitalization (# 21.5c/s)

$35.51 million $17.34 million

Cash total $10.759 million $10.960 million

Sales Revenue $21,619 million $16.469 million

Total Revenue $22,928 million $17.664 million

SUMMARY OF FINANCIALPERFORMANCE FY08

# Last sale 1/5/09

FY2008 FY2007

As per Annual Reports

For

per

sona

l use

onl

y

6

EBITDA $2.272 million $537,000

Profit $4.135 million $635,000

EPS 2.5 cents/share 0.38 cents/share

Major shareholder WHSP & Co. Ltd (28.55%) WHSP & Co. Ltd (28.55%)

Top 20 shareholders 59.75% of shares 55.1% of shares

SUMMARY OF FINANCIALPERFORMANCE FY08

FY2008 FY2007

As per Annual Reports

For

per

sona

l use

onl

y

7

FY08 KEY MILESTONES

• Improvements and increased production capacity at the Altona oil refinery.

• Commercial launch of new ThermoMAX™ encapsulation technology developed in conjunction with Food Science Australia/CSIRO.

• Secured 5 year supply contract with Mead Johnston & Company.

• Improved sales performance.• Acquisition of remaining 30% equity in Nu-Mega.• Recruitment of selected experienced personnel.

For

per

sona

l use

onl

y

8

0

1

2

3

4

5

FY06 FY07 FY08

Net Profit Tax Credit

million ($)

HISTORICAL FINANCIAL PERFORMANCE

For

per

sona

l use

onl

y

Summary Interim Results Clover 1H09

HY’09 HY’08 Variance(%)

Revenue $9.603M $9.989M Down3.9%

EBIT $2.064M $1.169M Up 76%

NPAT $1.609M $0.685M Up 134%

For

per

sona

l use

onl

y

10

CLINICAL RESEARCH

For

per

sona

l use

onl

y

11

PUBLICATIONS

For

per

sona

l use

onl

y

12

PRIORITIES FOR FY09

• Consolidate improved sales in infant formula applications. – Improve the product mix.

• Expand sales & distribution network.• Increase opportunities in food applications.• Selectively recruit for growth.• Move FFI to profitability• Continue development of encapsulation technology.• Identify new technical & commercial opportunities.• Update company image and communication.

For

per

sona

l use

onl

y

13

NEW CLOVER WEBSITE

For

per

sona

l use

onl

y

14

For

per

sona

l use

onl

y

15

NU-MEGA INGREDIENTS PTY LTD

Overview• Primary interest in the provision of HiDHA omega-3 tuna

oils/powders.• Refine crude tuna oil. • Prepare high quality oils & powders.• Utilise proprietary/patented encapsulation technologies for a range

of nutritional oils and other bioactives.• Process protects oil from oxidation (“fishy” taste & smell).• Major applications in infant formulas, foods & animal feeds.• HiDHA® oils reported to have many nutritional & health benefits. For

per

sona

l use

onl

y

16

NU-MEGA SALES & DISTRIBUTION NETWORK

SALES OFFICE MANUFACTURING SITE AGENTS

For

per

sona

l use

onl

y

17

WHERE DOES NU-MEGA SELL ITS INGREDIENTS?

Australia/New Zealand 39%

Asia 52%

Europe 8%

USA 1%

Infant formula Food Supplement Animal feed

AGM, November 2008

For

per

sona

l use

onl

y

18

Priorities in FY09• Increase sales in value added applications.• Increase sales & marketing presence.• Improve oil quality & increase capacity.• Finalise integration of Nu-Mega into Clover

Corporation.• Expand technology & new product

development.• Nutritional & clinical research.• Identify new complementary bioactive

opportunities.• Selective recruitment for growth.

NU-MEGA INGREDIENTS PTY LTD

For

per

sona

l use

onl

y

19

Challenges• Uncertain market conditions.

– Customers– Exchange rates

• Customers are reviewing ordering patterns.• Regional regulatory issues;

– Indonesia– Europe.

• Successfully expand sales through GTC Nutrition.

NU-MEGA INGREDIENTS PTY LTD

For

per

sona

l use

onl

y

20

Future Food Ingredients

For

per

sona

l use

onl

y

21

FUTURE FOOD INGREDIENTS

Overview• Manufacturing facility located in Moree, NSW.– Plant commissioned in December 2005.– CEO Warren Hannam– Plant Manager, QA & Production staff.

• Nu-Soya technology exclusively licensed worldwide from Byron Australia.

– Preparation of soy ingredients without the typical soy taste.

• Sales, Marketing & Applications managed by Nu-Mega Ingredients.

– Business Development Manager, Sales Personnel, Customer Service & Logistics and Applications Technologists.

For

per

sona

l use

onl

y

22

FUTURE FOOD INGREDIENTS

Product Range• Range of Enzyme Active Soy ingredients

– Flours, Grits, Splits & Flakes

• Range of Nu- Soya™ ingredients– Using a propriety process to produce whole bean, bland

flavoured Soy Ingredients– Flours, Grits, Flakes & Toasted Flakes

• Certification– Halal, Organic, Kosher, HACCP

For

per

sona

l use

onl

y

23

0

0.4

0.8

1.2

1.6

2

1H08 1H09

Sales Revenue

million ($)

FFI FINANCIAL PERFORMANCE1H09 – Sales revenue

For

per

sona

l use

onl

y

24

Focus during FY09• Continue to increase Nu-Soya™ sales, particularly in Asia.• Increase product range to maximize utilization of the plant.• Identify specialty nutritional &/or functional applications.• Develop opportunity in Asia for specialized organic soy

ingredients.• Continued applications development.• Expand sales coverage.• Control expenses.• Move to profitability.

FUTURE FOOD INGREDIENTS

For

per

sona

l use

onl

y

25

Outlook for FY09• Challenging period in an unsettled business environment.• Modest sales increase anticipated in FY09.• Control expenditure.• Address changes in regulations in Indonesia & Europe.• Expand the distribution and sales network in the America’s and

Europe in association with GTC Nutrition. • Further develop sales in infant formula applications, particularly in

Asia.• Continue new product and applications development.

CLOVER CORPORATION

For

per

sona

l use

onl

y

26

THANK YOUQuestions?

For

per

sona

l use

onl

y